Stoke Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
STOK$27.71+4.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed consolidated balance sheets
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $155,659 | $84,220 |
| Marketable securities - current | 187,886 | 200,450 |
| Accounts receivable | 4,451 | 5,936 |
| Prepaid expenses | 10,115 | 8,736 |
| Interest receivable | 1,690 | 1,969 |
| Other current assets | 6,880 | 4,389 |
| Total current assets | $366,681 | $305,700 |
| Marketable securities - long-term | 67,481 | 106,260 |
| Restricted cash - long-term | 3,227 | 227 |
| Operating lease right-of-use assets | 2,493 | 3,101 |
| Property and equipment, net | 3,395 | 3,146 |
| Total assets | $443,277 | $418,434 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $6,839 | $4,939 |
| Accrued and other current liabilities | 23,901 | 41,035 |
| Deferred revenue - current portion | 10,066 | 11,901 |
| Total current liabilities | $40,806 | $57,875 |
| Deferred revenue - net of current portion | 6,603 | 6,961 |
| Other long-term liabilities | 991 | 1,141 |
| Total long-term liabilities | 7,594 | 8,102 |
| Total liabilities | $48,400 | $65,977 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,240,347 and 58,921,999 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 6 | 5 |
| Additional paid-in capital | 942,704 | 849,624 |
| Accumulated other comprehensive (loss) income | (115) | 543 |
| Accumulated deficit | (547,718) | (497,715) |
| Total stockholders’ equity | $394,877 | $352,457 |
| Total liabilities and stockholders’ equity | $443,277 | $418,434 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.